ERBB2 and neoplasm: The use of matched therapy was relatively low in patients with tumor alterations such as ERBB2 mutation (14/43, 32.6%), MET amplification (32/99, 32.3%), KRAS G12C (8/135, 5.9%), and EGFR exon 20 insertion (1/25, 4.0%).